|
業務類別
|
-- |
|
業務概覽
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies witha contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue. |
| 公司地址
| c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051 |
| 電話號碼
| +41 616851900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.beonemedicines.com |
| 員工數量
| 12000 |
| Mr. Titus B. Ball |
Principal Accounting Officer |
-- |
26/02/2026 |
| Mr. John V. Oyler |
Chief Executive Officer and Chairman of the Board |
美元 1.13M |
28/04/2026 |
| Mr. Aaron Rosenberg |
Chief Financial officer |
美元 660.00K |
28/04/2026 |
| Dr. Xiaobin Wu, PhD |
President and Chief Operating Officer |
美元 862.41K |
28/04/2026 |
| Dr. Lai Wang, PhD |
President, Global Head of Research and Development |
美元 659.49K |
28/04/2026 |
| Mr. Chan Henry Lee |
Senior Vice President, General Counsel and Corporate Secretary |
美元 654.00K |
28/04/2026 |
|
|
| Mr. Anthony C. Hooper |
Independent Director |
28/04/2026 |
| Mr. John V. Oyler |
Chief Executive Officer and Chairman of the Board |
28/04/2026 |
| Mr. Michael J. Goller |
Independent Director |
28/04/2026 |
| Mr. Ranjeev Krishana |
Lead Independent Director |
28/04/2026 |
| Mr. Qingqing Yi |
Independent Director |
28/04/2026 |
| Dr. Xiaodong Wang, PhD |
Director |
28/04/2026 |
| Dr. Corazon Dating Sanders, PhD |
Independent Director |
28/04/2026 |
| Dr. Alessandro Riva, M.D. |
Independent Director |
28/04/2026 |
| Dr. Olivier Raymond Brandicourt, M.D. |
Independent Director |
28/04/2026 |
| Dr. Margaret Dugan, M.D. |
Independent Director |
28/04/2026 |
| Ms. Shalini Sharp |
Independent Director |
28/04/2026 |
|
|
|
|
